December 2023
1. SMYTH EC, Sundar R
   Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer.
   Lancet. 2023;402:2168-2170.
   

   >> Share

   
   May 2023
2. SHITARA K, Lordick F, Bang YJ, Enzinger P, et al
   Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 tr
   Lancet. 2023;401:1655-1668.
   

   >> Share

   
   March 2023
3. O'MAHONY D, Power SP, Power DG
   Human epidermal growth factor receptor 2-positive metastatic gastric cancer in complete sustained remission with trastuzumab.
   Lancet. 2023;401:772.
   

   >> Share

   
   July 2021
4. JANJIGIAN YY, Shitara K, Moehler M, Garrido M, et al
   First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
   Lancet. 2021;398:27-40.
   

   >> Share

   
   January 2021
5. 
   Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.
   Lancet. 2021;397:387-397.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share